Your SlideShare is downloading. ×
0
Pharmacovigilance
Pharmacovigilance
Pharmacovigilance
Pharmacovigilance
Pharmacovigilance
Pharmacovigilance
Pharmacovigilance
Pharmacovigilance
Pharmacovigilance
Pharmacovigilance
Pharmacovigilance
Pharmacovigilance
Pharmacovigilance
Pharmacovigilance
Pharmacovigilance
Pharmacovigilance
Pharmacovigilance
Pharmacovigilance
Pharmacovigilance
Pharmacovigilance
Pharmacovigilance
Pharmacovigilance
Pharmacovigilance
Pharmacovigilance
Pharmacovigilance
Pharmacovigilance
Pharmacovigilance
Pharmacovigilance
Upcoming SlideShare
Loading in...5
×

Thanks for flagging this SlideShare!

Oops! An error has occurred.

×
Saving this for later? Get the SlideShare app to save on your phone or tablet. Read anywhere, anytime – even offline.
Text the download link to your phone
Standard text messaging rates apply

Pharmacovigilance

2,467

Published on

What is an acceptable level of

What is an acceptable level of

Published in: Business, Health & Medicine
0 Comments
2 Likes
Statistics
Notes
  • Be the first to comment

No Downloads
Views
Total Views
2,467
On Slideshare
0
From Embeds
0
Number of Embeds
0
Actions
Shares
0
Downloads
140
Comments
0
Likes
2
Embeds 0
No embeds

Report content
Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
No notes for slide

Transcript

  • 1. Pharmacovigilance Are you concerned enough? December 2011
  • 2. What is Pharmacovigilance (PV)?The science and activities relating to the detection, assessment, understanding and prevention of adverse effects or any other medicine-related problem – World Health Organization
  • 3. Pharmaco - Vigilance Pharmaco = medicine Vigilare = to watch  alert watchfulness  wakefulness  watchfulness in respect of danger; care; caution; circumspection  the process of paying close and continuous attention
  • 4. Definition Adverse Drug Reaction  "A response to a drug which is noxious and unintended, and which occurs at doses normally used in man for the prophylaxis, diagnosis, or therapy of disease, or for the modification of physiological function." Adverse Event  Any untoward medical occurrence that may present during treatment with a pharmaceutical product but which does not necessarily have a causal relationship with this treatment Side Effect  Any unintended effect of a pharmaceutical product occurring at doses normally used in man which is related to the pharmacological properties of the drug
  • 5. The Aims of Pharmacovigilance To improve patient care and safety To improve public health and safety To contribute to the assessment of benefit, harm, effectiveness and risk of medicines To promote understanding, education and clinical training
  • 6. What to Report?SERIOUS ADRS A serious adverse event (experience) or reaction is any untoward medical occurrence that at any dose:  results in death,  is life-threatening,  requires inpatient hospitalization of prolongation of existing hospitalization,  is a congenital anomaly/birth defect. NOTE: The term “life-threatening” in the definition of “serious” refers to an event in which the patient was at risk of death at the time of the event; it does not refer to an event which hypothetically might have caused death if it was more severe.
  • 7. Adverse Reactions:Possible Causes Intrinsic factors of the drug  Pharmacological  Idiosyncratic  Carcinogenicity, Mutagenicity  Teratogenicity Extrinsic factors  Adulterants  Contamination Underlying medical conditions Interactions Wrong usage
  • 8. What Should be Reported New drugs  Report all suspected reactions including minor ones For established or well known drugs  All serious, unexpected, unusual ADRs Change in frequency of a given reaction ADRs to generics not seen with innovator products ADRs to traditional medicines
  • 9. What Should be Reported All suspected drug-drug, drug-food, drug-food supplement interactions  Statement highlighting marine source of supplements such as glucosamine so that can be avoided by those with allergy to sea food ADRs associated with drug withdrawals ADRs due to medication errors  eg vincristine given IT ADRs due to lack of efficacy or suspected pharmaceutical defects
  • 10. Why ADRs are important ? 5% of hospital admissions Death of 1 in 1000 medical inpatients Complicates drug therapy Decrease compliance
  • 11. Why ADRs are important ?30 – 50% of all ADRs are preventable
  • 12. Why do we needpharmacovigilance?
  • 13. Why do we need pharmacovigilance?Reason 1: Humanitarian concern –  Insufficient evidence of safety from clinical trials  Animal experiments  Phase 1 – 3 studies prior to marketing authorization
  • 14. Why do we need pharmacovigilance?Reason 2 Medicines are supposed to save lives Dying from a disease is sometimes unavoidable; dying from a medicine is unacceptable. WHO. Geneva 2005
  • 15. Why do we need pharmacovigilance?Reason 3: ADRs are expensive !! 6.5% of admissions are due to ADRs Seven 800-bed hospitals are occupied by ADR patients
  • 16. Cost of ADRs ? ADR related cost to the country exceeds the cost of the medications themselves
  • 17. Why do we need pharmacovigilance?Reason 4: Promoting rational use of medicines and adherence
  • 18. Pharmacovigilance system Records medication related errors Analyses those errors Implements interventions Promotes patient safety Prevent preventable errors Actionable learning system ARGUS – ARIS Global – Phase Forward (Empirica)
  • 19. Passive - ProactiveFuture Pro-Active State Risk Management Aggregate Reporting Signal Detection Adverse Case Management
  • 20. Passive - ProactiveCurrent Passive State Risk Management Signal Detection Aggregate Reporting
  • 21. What can we do?
  • 22. What can we do? Develop procedures for the identification, reporting and follow up of adverse drug events
  • 23. What can we do? Assess the current technology used in the drug safety process and assist in implementation of new systems
  • 24. What can we do? Evaluate data quality and data integrity controls in place
  • 25. What can we do? Prepare risk minimization action plan (RiskMAP)
  • 26. What can we do? Assess current drug safety and pharmacovigilance training programs
  • 27. What can we do? Reconcile internal processes for recording safety data received from multiple sources
  • 28. For more information:Monica Dema, Manager New Business Development 973.658.3133 Or Monica.Dema@RCMT.com Or @MonicaDema

×